Periodontitis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Periodontitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Periodontitis - Pipeline Review, H2 2014', provides an overview of the Periodontitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Periodontitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Periodontitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Periodontitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Periodontitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Periodontitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Periodontitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Periodontitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Periodontitis Overview 6
Therapeutics Development 7
Pipeline Products for Periodontitis - Overview 7
Pipeline Products for Periodontitis - Comparative Analysis 8
Periodontitis - Therapeutics under Development by Companies 9
Periodontitis - Therapeutics under Investigation by Universities/Institutes 10
Periodontitis - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Periodontitis - Products under Development by Companies 13
Periodontitis - Products under Investigation by Universities/Institutes 14
Periodontitis - Companies Involved in Therapeutics Development 15
CSL Limited 15
Ensoltek Co., Ltd. 16
KAEL-GemVax Co., Ltd. 17
Kaken Pharmaceutical Co., Ltd. 18
NeoStem, Inc. 19
Periodontitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Cp-40 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug to Antagonize C5aR for Periodontitis - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drugs for Periodontitis - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GM-0111 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Hesed-3000 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
KCB-1D - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
POD CRC-OHS - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit Lysine Decarboxylase for Periodontitis - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
tertomotide - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Periodontitis - Recent Pipeline Updates 42
Periodontitis - Dormant Projects 44
Periodontitis - Product Development Milestones 45
Featured News & Press Releases 45
May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment 45
Nov 20, 2012: NeoStem Receives Notification Of $1.2m NIH Grant Award For First Clinical Study Of VSEL Technology In Humans 46
Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 47
Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Periodontitis, H2 2014 7
Number of Products under Development for Periodontitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Periodontitis - Pipeline by CSL Limited, H2 2014 15
Periodontitis - Pipeline by Ensoltek Co., Ltd., H2 2014 16
Periodontitis - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 17
Periodontitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 18
Periodontitis - Pipeline by NeoStem, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Periodontitis Therapeutics - Recent Pipeline Updates, H2 2014 42
Periodontitis - Dormant Projects, H2 2014 44